Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

112.56 -4.54 (-3.88%)
Official Closing Price Updated: 7:00 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
News headline image
Buybacks Galore: 3 Mega-Caps Just Approved Billions in Buybacks
Check out these three mega-cap names, valued over $200 billion each, that just authorized a combined $28 billion in buybacks. 
Via MarketBeat
Topics Earnings Economy Intellectual Property
News headline image
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies ↗
The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment. 
Via Stocktwits
News headline image
Securities Fraud Investigation Into Merck & Co (MRK) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
MERCK & CO., INC. (NYSE: MRK) INVESTOR ALERT: Investors With Large Losses in Merck & Co., Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Looking Into Merck & Co's Recent Short Interest ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 13 Analysts Discuss Merck & Co Stock ↗
 
Via Benzinga
News headline image
Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports ↗
Trump's proposed 25% tariffs on auto, semiconductor, and pharmaceutical imports have rattled markets and could affect ETFs with heavy exposure to these sectors. 
Via Benzinga
Topics ETFs Government World Trade
News headline image
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Merck & Co. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Filed Against MRK
From Robbins LLP
Via GlobeNewswire
News headline image
Why NYSE:MRK is a Top Pick for Dividend Investors. ↗
Why MERCK & CO. INC. (NYSE:MRK) provides a good dividend, while having solid fundamentals. 
Via Chartmill
News headline image
Decoding Merck & Co's Options Activity: What's the Big Picture? ↗
 
Via Benzinga
News headline image
Europe Approves Merck's Cancer Drug For Two Indications ↗
Merck's Welireg receives conditional EU approval for VHL disease-associated tumors and advanced RCC, expanding its global presence across 30+ countries. 
Via Benzinga
News headline image
This Moderna Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
From Merck & Co., Inc.
Via Business Wire
News headline image
Trump's Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich ↗
Robert Reich has termed Donald Trump's taxation policies as an "absolutely shameless giveaway," that could shoot up deficit to $4.6 trillion. 
Via Benzinga
Topics Government
News headline image
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
MRK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
MarketBeat Week in Review – 02/10 - 02/14
Despite many negative headlines, stocks are trading near all-time highs; next week will be a shortened trading week, with most of the monthly economic data in 
Via MarketBeat
Topics Credit Cards Economy Government
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
In a market where value is scarce, NYSE:MRK offers a refreshing opportunity with its solid fundamentals. ↗
MERCK & CO. INC. has caught the attention as a great value stock. NYSE:MRK excels in profitability, solvency, and liquidity, all while being very reasonably priced. 
Via Chartmill
News headline image
MRK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
Rosen Law Firm Urges Merck & Co., Inc. (NYSE: MRK) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump's Secretary Of Health: Health Care Stocks To Watch ↗
The U.S. Senate voted on Thursday to confirm President Donald Trump's nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Benzinga
Topics Government
News headline image
3 Blue-Chip Dividend Stocks Trading at Multiyear Lows ↗
Via The Motley Fool
News headline image
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever. ↗
Via The Motley Fool
News headline image
Rosen Law Firm Encourages Merck & Co. Inc. Investors to Inquire About Securities Class Action Investigation – MRK
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Neuphoria Stock Jumps On Triggering $15M Milestone Payment From Merck For Alzheimer's Study: Retail Interest Explodes ↗
This payment represents the second milestone in the collaboration between Neuphoria and Merck, with Neuphoria potentially eligible for up to $450 million in additional milestone payments. 
Via Stocktwits
News headline image
Gilead Sciences Beats Q4 EPS Forecast ↗
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. 
Via The Motley Fool
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.